Sector: Healthcare
findl.com provides a comprehensive suite of standardized financial statement data and an assortment of calculated metrics sourced directly from SEC filings, and meticulously cleansed and verified, ensuring reliability. To get the complete financial statement history in quarterly and annual resolution for VRTX, sign up here.
Income Statement
Revenue
$9.9bn
Gross Profit
$8.6bn
Earning before Tax
$4.4bn
Net Income
$3.6bn
Net Income Common Shareholders
$3.6bn
EPS
14.05
Balance Sheet
Cash
$10.4bn
Debt
$724.7m
Assets
$22.7bn
Liabilities
$5.1bn
Equity
$17.6bn
Enterprise Value
$94.5bn
Cash Flow Statement
Net Cash from Operations
$3.5bn
Net Cash from Investing
$-3.1bn
Net Cash from Financing
$-0.6bn
Net Cash Flow
$-0.1bn
Free Cash Flow
$3.3bn
Free Cash Flow per Share
$12.95
Metrics
Price to Equity
28.97
Price to Equity (Damodaran)
28.96
Price to Book
5.96
Net Margin
0.37
Return on Equity
0.23
Return on Sales
0.45
Get immediate access to 5-years of reference grade data for VRTX for free.
Sign upVertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company''s pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Company Info
Industry
Biotechnology
Employees
5,400
Address
50 Northern Avenue
Boston, MA 02210
United States
Phone
617 341 6100
Website
Last Updated
2024-02-19
Available Data
Standardized Financial Statements
EOD Price History
Corporate Actions
Institutional Holdings
Insider Transactions
Copyright © findl 2024. All rights reserved.